What Sardocor does

Sardocor is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. It operates as a wholly owned subsidiary of the Medera Group, developing gene and cell therapies for rare and common cardiovascular, pulmonary, and vascular diseases. The company's lead therapeutic modality is recombinant adeno-associated viral vector (AAV) gene therapy, specifically AAV serotype 1 capsid carrying the human SERCA2a gene (AAV1/SERCA2a), which targets calcium dysregulation in cardiomyocytes — a validated mechanism in heart failure pathology. The science is grounded in over three decades of foundational cardiac gene therapy research originated at Massachusetts General Hospital by founder Dr. Roger Hajjar.

Sardocor's clinical pipeline centers on SRD-001, its lead AAV1/SERCA2a gene therapy candidate delivered via a proprietary intracoronary infusion method. The company holds three open FDA Investigational New Drug (IND) approvals covering Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with HFpEF and DMD-CM designated as First-in-Human gene therapies for those indications. FDA Fast Track designation was granted to both the HFpEF and DMD-CM programs in early 2026. Manufacturing scale has reached 1,000 doses of SRD-001 available for patient dosing. The company also pursues earlier-stage programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure, and leverages Novoheart's bioengineered human mini-heart assays for disease modeling and dosing optimization under FDA Modernization Act 2.0.

The business model is pre-commercial: Sardocor is a pre-revenue, clinical-stage biotech that distributes its therapies exclusively through FDA-regulated clinical trial sites and intends to commercialize via traditional pharmaceutical channels post-approval. Revenue mechanics are expected to be one-time license/product sales of approved gene therapies rather than recurring subscription revenue. The company actively courts investor relationships to fund ongoing clinical development, has an Expanded Access program, and recruits patients directly through its website for trial enrollment. Its headcount of 11–50 reflects an early-stage operating footprint appropriate to a sponsor of three concurrent Phase-stage trials, with the parent Medera Group providing corporate infrastructure.

Name

Sardocor

Legal name

Sardocor Corp

Website

https://sardocor.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Sardocor is a clinical-stage gene therapy subsidiary of Medera Group developing AAV1/SERCA2a treatments for heart failure and Duchenne Muscular Dystrophy-associated cardiomyopathy, with three FDA IND approvals and Fast Track designations.

Ownership category

akta.pro rank

Product category

Cardiac Gene Therapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)

akta.pro secondary industries

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Cardiac gene therapy
• AAV gene therapy
• Heart failure therapeutics
• Duchenne cardiomyopathy
• SERCA2a gene transfer

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Gene Therapy Commercialization: Pre-revenue clinical-stage biotech company developing gene therapy products for heart failure and related cardiomyopathies. Revenue generation will come from FDA-approved gene therapy products commercialized after successful clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sardocor develops gene therapies for cardiac, pulmonary, and vascular diseases using recombinant AAV1/SERCA2a vectors delivered via a proprietary intracoronary method. Its lead candidate SRD-001 has 1,000 doses manufactured and is being advanced through three FDA IND-approved clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF), and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), with additional pipeline programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Product overview

Sardocor is a clinical-stage biopharmaceutical company developing novel gene therapies for cardiac, pulmonary, and vascular diseases. The company's lead product is SRD-001, a gene therapy delivered via a proprietary intracoronary method that has completed manufacturing of 1,000 doses. Sardocor operates three FDA IND-approved gene therapy clinical trials: HFpEF (Heart Failure with Preserved Ejection Fraction), HFrEF (Heart Failure with Reduced Ejection Fraction), and DMD-CM (Duchenne Muscular Dystrophy-associated Cardiomyopathy), with HFpEF and DMD-CM both receiving FDA Fast Track designation. The company leverages SERCA2a gene transfer technology using recombinant adeno-associated viral vectors (AAV) and bioengineered human heart-based assays from Novoheart for disease modeling. The pipeline also includes programs in pulmonary hypertension, pulmonary fibrosis, restenosis, and arteriovenous fistula failure.

Differentiator

Problem solved

Functional benefit

Products and services

• SRD-001 Gene Therapy Candidate AAV1/SERCA2a gene therapy drug candidate administered via Sardocor's proprietary intracoronary delivery method to infuse gene therapy directly into the heart for patients with cardiac diseases. 1,000 doses have been manufactured.
• HFpEF Gene Therapy Clinical Program First-in-Human gene therapy clinical program targeting Heart Failure with preserved Ejection Fraction (HFpEF), a condition with no disease-modifying therapies currently available; granted FDA Fast Track designation.
• HFrEF Gene Therapy Clinical Program Gene therapy clinical program targeting Heart Failure with reduced Ejection Fraction (HFrEF), a progressive and irreversible syndrome; aims to restore SERCA2a function via AAV gene transfer.
• DMD-CM Gene Therapy Clinical Program First-in-Human gene therapy clinical program targeting cardiomyopathy in Duchenne Muscular Dystrophy (DMD-CM); granted FDA Fast Track designation.
• Pulmonary Hypertension Gene Therapy Program Pipeline gene therapy program targeting pulmonary hypertension, a condition where high blood pressure in the pulmonary arteries causes damage to the right side of the heart.
• Pulmonary Fibrosis Gene Therapy Program Pipeline gene therapy program targeting pulmonary fibrosis, a lung-scarring condition that blocks oxygen transfer into the bloodstream.
• Restenosis Gene Therapy Program Pipeline gene therapy program targeting restenosis, a condition where treated arteries become narrowed again after treatment.
• Arteriovenous Fistula Failure Gene Therapy Program Pipeline gene therapy program targeting arteriovenous fistula failure, where surgically created dialysis access never becomes usable or fails within three months.

Quantifiable outcome

• 1,000 doses of SRD001 manufactured and made available to patients
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Medera GroupcoreStrategic or Co-development PartnerSardocor is a fully owned subsidiary of Medera Group. Sardocor operates as a division of Medera, advancing a pipeline of disease-modifying gene therapies developed by the Medera team.
• NovoheartcoreTechnology or IntegrationSardocor uses Novoheart's proprietary, world's first human mini-heart technology for disease modelling and therapeutic discovery. This bioengineered human heart-based assay is used to titrate optimal dosages for gene therapy candidates in accordance with FDA Modernization Act 2.0 for human relevance and accuracy.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Broad incumbents

• uniQure: Established gene therapy company with AAV platform and programs in cardiovascular disease (e.g., AMT-101 for refractory angina using SERCA2a). Direct overlap on SERCA2a gene therapy mechanism and cardiovascular focus, but broader portfolio across multiple disease areas.
• BioMarin Pharmaceutical: Commercial-stage gene therapy company with multiple approved and clinical-stage AAV products for rare diseases (e.g., Roctavian for hemophilia A). Comparable gene therapy modality and rare disease commercial strategy, though broader portfolio and much larger scale.
• AskBio (Bayer): Acquired by Bayer; develops AAV-based gene therapies across multiple disease areas including cardiac (congestive heart failure program based on Hajjar's earlier SERCA2a work licensed from Dr. Hajjar). Highly relevant incumbent that previously licensed the underlying SERCA2a technology.

Direct peers

• Capricor Therapeutics: Clinical-stage biotech developing cell and exosome-based therapies for Duchenne muscular dystrophy and related cardiomyopathies. Direct overlap on DMD-CM indication and complementary cell/gene therapy modality for cardiac disease.
• Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiac and CNS indications, including AAV-based therapies for genetic cardiomyopathies and Friedreich's ataxia cardiomyopathy. Directly comparable platform (AAV gene therapy), indication overlap (cardiac), and stage (clinical).
• Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV-based therapies for rare diseases, with a cardiac program (RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy). Comparable platform technology and rare cardiac indication focus.
• Lexeo Therapeutics (duplicate entry superseded): Omitted in favor of stronger direct peers above.
• Tenaya Therapeutics: Clinical-stage biotech developing gene therapies for genetic and acquired heart disease, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy. Directly comparable AAV-based cardiac gene therapy platform and similar disease-modifying positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sardocor